VerImmune key facts
as of Oct 2026- Developer of a virus-inspired therapeutic delivery platform designed to leverage the natural geometric structure of viruses for targeted payload transport.
- VerImmune is valued at approximately $30.0M as of Oct 2026, set at its later-stage round, Jul 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $10.0M across 2 recorded rounds; the latest was Seed Round ($4.5M) in Aug 2024.
- Notable investors include US National Science Foundation, Mana Ventures, Gaingels, TEDCO, Ulu Ventures — 12 tracked in total.
- VerImmune has filed 2 Form Ds with the SEC since 2022, most recently Sep 2024 ($4.5M sold to 6 investors).
- Status: Privately Held (backing).
Valued at $30.0M at its later-stage round, Jul 2025. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch VerImmune: the Monday email on marks, rounds and moves
VerImmune funding rounds
2 roundsWho backs VerImmune
12+Membership and data by Private Market View
VerImmune valuation
VerImmune was valued at $30 million at its later-stage round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has VerImmune raised?
VerImmune has raised $10 million in total; 2 of its rounds are on record. The largest on record was a $4.5 million seed round in Aug 2024.
VerImmune has filed 2 Form Ds with the SEC since 2022, most recently in Sep 2024 ($4.5 million sold to 6 investors).
VerImmune investors
12 investors are on record for VerImmune, including US National Science Foundation, Mana Ventures, Gaingels and TEDCO. By type, the record holds 7 venture capital firms. The seed round in Aug 2024 drew 6 investors.
About VerImmune
Developer of a virus-inspired therapeutic delivery platform designed to leverage the natural geometric structure of viruses for targeted payload transport. The company offers a self-assembling Virus-inspired Particle system that carries diverse therapeutic payloads for oncology, autoimmunity, and animal health applications, enabling researchers and developers to pursue targeted treatment strategies across multiple disease areas.
- Sector
- Healthcare
- HQ
- Germantown, MD, United States
- Founded
- 2019
- Employees
- 8
- Website
- verimmune.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.